Lamark Biotech raises Rs 6.5 Cr in pre-Series A round

Innovation-led biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A funding round led by IAN Group.

The round also saw participation from IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK.

The company had earlier raised $41.3K in seed funding led by VIT-TBI and other investors.

Read also- Bambrew Raises Rs 90 Cr Funding to Scale Sustainable Packaging Innovation Globally

With the new funding, the company plans to speed up the development of thermostable insulin and expand its biologics platform to make advanced treatments more accessible globally.

“We’re accelerating our thermostable insulin program and expanding ProteoStrong to more critical therapeutics using this resource. Our priority is clear- make safe and high-efficacy biologics for all. We believe, ‘if it is not accessible, it not a medicine’,” said Vaibhav Bhatia, who is also the CEO of the company.

Padmaja Ruparel, Co-founder, IAN Group, said, “Investment in Lamark represents IAN’s investment strategy to invest and grow innovations that solve real problems. The solution is critical in low-resource environments, with Lamark's thermostable biologics which can make critical treatments accessible at a low cost for millions of people, both in India and globally.”

About Lamark Biotech

Founded in 2018 by Vaibhav Bhatia, Lamark Biotech is transforming how treatments for chronic and life-altering diseases are delivered. The company’s proprietary ProteoStrong platform stabilizes delicate protein-based drugs—like insulin, monoclonal antibodies, and enzymes—without changing their molecular structure.

Lamark is addressing a major challenge in the healthcare ecosystem, reducing reliance on cold chain logistics and making life saving drugs more accessible and affordable worldwide.

Ahmedabad-based Lamark Biotech is developing a new class of temperature-resilient biologics designed to remain effective even in extreme conditions—making them ideal for regions with limited cold storage. The startup operates with strong R&D support from Venture Center, NCL Innovation Park in Pune.

Its lead product, InsulinStrong, targets the ₹4,000 crore Indian insulin market and aims to expand across Southeast Asia and the UAE. Lamark is also extending its platform to address conditions like diabetic eye disease and cancer immunotherapy.

Over the next 24 months, Lamark Biotech plans to file new international patents, start early-stage clinical trials, and form strategic partnerships with pharmaceutical companies, contract development and manufacturing organizations (CDMOs), and global health agencies.

Advertisment